1

What do women want to see in a personalized breast cancer risk report?

A qualitative study of Asian women of two countries

Fatma Aldila[1*¶], Fiona Ng FJ[1¶], Jessica Audrienna[1], Lynn Lim SJ[1], Shannon Tang[1], Sabrina Gabriel Tanu[1],

Eric Aria Fernandez[1], Faustina Audrey Agatha[2&], Marco Wijaya[2&], Stevany Tiurma Br Sormin[2&], Levana Sani[1],

Astrid Irwanto[1], Samuel J. Haryono[2], Jingmei Li[3], Alexandre Chan[4], Mikael Hartman[5,6]

[1]NalaGenetics Pte Ltd (NalaGenetics), Singapore

[2]SJH Initiatives, MRCCC Siloam Hospitals Semanggi, Jakarta Indonesia

[3]Agency for Science, Technology and Research (A*STAR), Genome Institute of Singapore, Singapore

[4]University of California, Irvine, School of Pharmacy & Pharmaceutical Sciences, USA

[5]Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore

[6]Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore

* Corresponding author

E-mail: clinicalstudies@nalagenetics.com (FA)

[¶]These authors contributed equally to this work.

[&]These authors also contributed equally to this work.

Abstract

Introduction: A breast cancer risk assessment tool using Polygenic Risk Score (PRS) assessment of 313 single nucleotide polymorphisms and a risk prediction algorithm from the Gail Model had been established and validated for Asian population. Through facilitated focus group discussions, we assessed the preferences of women from two Asian countries regarding the presentation of risk results, the level of detail provided for explanations, and recommendations for follow-up actions.

Methods: This qualitative study was conducted between July to October 2022 with Asian women above the age of 25. We structured a focus group discussion to evaluate the views and perceptions of women in Indonesia and Singapore in relation to personalized breast cancer risk assessment. All participants received either a detailed high-risk or low-risk mock report and were assigned to either high-risk result or low-risk result focus group based on the report they had randomly received. All focus group discussion content was then thematically analyzed.

Results: In Singapore, participants preferred a detailed report as it was comprehensive and provided follow-up steps and information to manage their breast cancer risk. Participants raised the need for visuals without colors that project intimidation as well as a summary on the first page of the report to support interpretations. Regarding content, participants expected recommended actions to reduce their risk. Communication styles could also be improved with simplified language. Furthermore, we identified anxious responses from participants receiving high-risk results and relieved responses from those receiving low-risk results. Overall, participants found the report useful and would like to see similar reports on other diseases in the future.

Conclusion: Overall, most patients prefer a test report to be well balanced between

content and complexity. The study also highlighted the importance of psychological impact of

patients receiving their test reports, which is greatly influenced by the patients' degree of

understanding and interpretation of the reports. Finally, as most patients would likely increase

their engagement with their physicians upon receiving their test results, future studies could be

extended to physicians who are directly involved in the patient care delivery of breast cancer

prevention.

Introduction

Breast cancer (BC) is the most common cancer and the leading cause of cancer-related

deaths among women. In 2020, there were 2.3 million new cases of women diagnosed with BC

and 685 000 deaths worldwide [1]. In the past few years, there has been a rise in popularity of

studies using polygenic risk scores (PRS) to determine a person's risk of BC [2-4] PRS, which

sums the impact of multiple common genetic variants to estimate disease risk, has demonstrated

the potential to improve the identification of individuals at high risk of developing BC [5].

Early diagnosis of BC through mammography screening has been shown to reduce deaths

from the disease [6,7]. However, mammography does not come without risks. False positive tests

and overdiagnosis of tumors that may never advance into a clinical stage that endanger life are

commonly cited downsides of mammography screening [8,9]. In Asia, the benefits of

mammography screening are further impeded by the lack of organized screening programs, and

the fear of mammogram procedural pain [10-12].

Numerous risk predictors for BC, such as family history, classical BC risk factors,

mammographic density, and PRS, thus play a pivotal role in determining which women are most

likely to benefit from surveillance [13-16]. A BC risk assessment tool using PRS assessment of

313 single nucleotide polymorphisms and a risk prediction algorithm from the Gail Model had

previously been established [17,18], and validated [19-21] for Asian population. The generated

risk report provides information on BC risk stratification and personalized risk-reducing

recommendations, which will help doctors in delivering tailored care plans. To improve the

communication and delivery of genetic based screening test reports, for example, studies were

conducted in the United States [22] and the United Kingdom [23] to provide recommendations

on the report format. However, the findings reported in the two studies may or may not be

applicable to all clinical settings, especially in the Asian context and for BC in particular.

Beyond healthcare providers, the potential impact of disclosing the BC risk assessment

report to its targeted customers, namely healthy women with no history of BC, is still not well

understood. Almost all published studies are sourced from non-Asian countries where acceptance

of BC risk assessment test could be different from the Indonesian and Singaporean populations.

Hence, effective ways of returning personal risk information comprising predictions from

various genetic and non-genetic risk factors still have much room for improvement. Through

facilitated focus group discussions (FGD), we assessed the preferences of women from two

Asian countries regarding the presentation of risk results, the level of detail provided for

explanations, and recommendations for follow-up actions.

Methods

This was a qualitative study involving focus groups. FGD was deemed most suitable as it allowed for a deeper discussion on the perception of healthy women in Indonesia and Singapore in relation to BC risk assessment testing. Indonesia and Singapore were chosen because the countries have different policies and practices of BC screening programs. The clinical BC screening program in Indonesia is opportunistic designed as a response to symptoms reported by women. Meanwhile, Singapore has adopted a nation-wide BC clinical screening program referred to as BreastScreen Singapore since 2002 [24,25].

The study was conducted in Indonesia from September to October 2022 and in Singapore from July to August 2022. The Standards for Reporting Qualitative Research (SRQR) was utilized as reporting guidelines. The checklist is shown in S1 File.

Ethical approval for the study was obtained from the Parkway Independent Ethics Committee of Singapore under approval number PIEC/2022/013 and Ethical Committee of Atma Jaya Catholic University of Indonesia under approval number 0007W/III/PPPE.PM.10.05/09/2022. Written informed consent was sought from all the participants before they were enrolled in the study.

Eligibility criteria and recruitment

The inclusion criteria included women aged above 25 who have not been diagnosed with BC and are able to use the Zoom application.

Convenience sampling method was used both in Indonesia and Singapore. The study was

promoted via social media platforms, such as Instagram and LinkedIn, online newsletters, and

direct promotion to potential participants by the study team members. Online study promotion

was selected because online marketing would be primarily used to advertise the product in the

future. Interested individuals were asked to fill out the Microsoft Forms so that the study team

members could contact them to check their eligibility and time availability. This form allowed

the study team members to identify the individual participants' information, including name, age,

and an explanation of the study procedures was then provided to the eligible individuals, and

informed consent was taken via HelloSign. The participants were offered electronic money

credits valued at Rp 50.000 in Indonesia or SGD 20 in Singapore as an incentive to participate.

Participation and withdrawal were fully voluntary.

Sample size consideration

124   Researchers aimed to arrange four different sessions of FGD in each country. Based on

125   existing literature, data saturation of 90% or higher could be achieved by conducting at least four

126   sessions of FGD [26,27].

Development of focus groups and interview guide

Prior to the focus groups, all participants received either a detailed high-risk or low-risk

mock report that is currently under development by NalaGenetics (S2 File). Participants from

Indonesia received a translated version of the report in Bahasa Indonesia. Apart from the detailed

mock risk report, participants in Singapore also received a simplified version of the mock risk

report (S4 File), which was adapted from an ongoing research program [28]. Both reports

contained recommendations that help patients manage their risks and a personalized screening

plan to identify the risk of BC early, improving the effectiveness of treatment. All participants

were then assigned to either the low-risk result or high-risk result focus group based on the report

they had randomly received. The decision to separate the participants into two cohorts was based

on the assumption that people who receive high-risk results may have different opinions from

those receiving low-risk results.

All FGDs were conducted via Zoom application. FGDs in Indonesia were conducted in

Bahasa Indonesia by FA, while FGDs in Singapore were conducted in English by FN. Both

facilitators were part of the investigation team, and they had both undergone training for FGD.

FA also had previous experience moderating a few sessions of FGD.

Based on the FGD simulations that had been previously conducted, the maximum

number of participants was capped at five per FGD session to give each participant enough time

to answer a question before moving on to the next question. Participants were reminded that

there were no right or wrong answers, allowing them to freely express their opinions. The

questions asked during FGD covered aspects that were related to room for improvement in the

report prototype. (S3 File). Confirmatory questions were asked following the closed-ended

questions to avoid bias.

Data collection

During the FGD, the facilitator began each session by introducing all members of the study team. Next, participants were reminded of the background and objectives of the study. An explanation and interpretation of the report were also provided. All discussions were digitally recorded using the recording feature via the Zoom application.

To ensure that the participants are actively engaged in the discussion, all participants were requested to turn on their web camera during their sessions. The facilitator aimed to finish each session within 90 minutes to prevent exhausting the participants, while ensuring that sufficient time was allocated to them before moving on to the next question.

Data analysis

All audio recordings were manually transcribed verbatim and reviewed by two independent study team members for assurance. Participants' identities were anonymized by assigning them a unique code. Language translation to English was done manually for all FGD responses collected in Bahasa Indonesia.

Through an iterative comparison, inductive thematic analysis was performed. This analysis was done by coding the FGD participants' responses; similar codes were then subsequently grouped together to obtain sub-themes. Finally, relevant sub-themes were grouped together into broader themes. Any differences in opinions were resolved through a discussion among the study team members. No specific framework was used to assist with the analysis as the nature of the study was fully exploratory.

Availability of Data and Materials

Permission to access patient data is restricted to the corresponding authors only. The shared information in this focus group comprises of personal details that will not be made available for publicity due to ethical and legal reasonings. Furthermore, anonymization of the complete transcript cannot be guaranteed due to a small group size.

Results

Initially, a total of 64 individuals expressed their interest in participating in this study. Out of the 22 participants that were excluded from the recruitment, 2 were lost to follow up, 2 did not meet the inclusion criteria, 2 decided not to continue with the recruitment process, and 16 could not make it for the allocated time slot. This reduced the number of participants that were recruited to 42. Out of the 42 participants recruited, 10 participants did not manage to attend the FGD due to sudden work or other personal commitments. The final number of participants was 32, with recruitment flow as shown in Figure 1.

Fig 1. Flowchart of participant recruitment. Participants Recruitment Flow

The demographics of the participants involved in the FGD in Indonesia and Singapore

were summarized in Table 1. In Indonesia, participants were between 25 to 30 years old with a

mean age of 27.9 years. There are only 14 participants who disclosed their ethnicity background.

Eighty percent of the participants were Indonesian (n=12) but nine of them were from Jawa

ethnic group. In Singapore, the age range of the participants involved was 25 to 49 years old with

a mean age of 37.2 years. Eighty two percent of the participants were Chinese (n=14) while the

rest were Indian (n=2) or Burmese (n=1).

Table 1. Participants demographics

	Indonesia (n=15)	Singapore (n=17)
Mean Age (years, range)	27.9 (25-30)	37.2 (25-49)
Ethnicity		
Indonesia*	12 (80.0%)	-
Chinese	1 (6.7%)	14 (82.3%)

Indian	-	2 (11.8%)
Others/undisclosed	2 (13.3%)	1 (5.9%)

*Specific ethnic groups included: Jawa (n=9), Lampung (n=1), Minangkabau (n=1), Mixed (n=1)

A total of ten sessions of FGD were conducted for this study. Each session consisted of

between 2 and 5 participants. The discussions with the low-risk result cohort were attended by a

total of 18 participants divided into five different sessions. Similarly, the discussions with the

high-risk result cohort were attended by a total of 14 participants split into five different sessions.

Four key themes were identified from the FGD sessions carried out. The first key theme

gave insight on patients' preference towards receiving a genetic risk report. The second key

theme provided information around the areas of improvement for the report prototype, and this

included subthemes such as the content of the report, the design of the report, and the overall

communication of the report. The third key theme provided insight into the potential impact of

the BC risk assessment report on users. Meanwhile, the last key theme informed healthy

women's perceptions and expectations of BC risk assessment testing.

213 Theme 1: More participants favor more information regarding their

214 risk profiles (Singapore FGD participants only)

In Singapore, participants were asked to compare the detailed report against the

simplified report (S4 File). Almost all participants would prefer the detailed report, as they felt

that it was more comprehensive in reporting their risk results and providing information on the

follow-up steps to manage their BC risk.

"I prefer the one with more information … I feel that the other report is too short

… [from the detailed report], you can find out which percentile you are [at] as

compared to the general population … and I think there is more information with regards

to the lifestyle changes [that] you can make." (Singapore FGD Participant 5, High-risk

result report recipient)

Nonetheless, two of the Singapore FGD participants preferred the simplified report stated

that a detailed report was not needed and would rather consult with their physicians if they

needed additional information.

Theme 2: Areas of improvement

Subtheme 2.1 The design of the report

In general, participants stated that the report looked visually appealing and

comprehensive, and the design was attractive. Some participants also expressed that they enjoyed

the colorful and user-friendly report. Nevertheless, many participants reported constantly that

some important information was not clearly visible due to the use of a very subtle pink font color

or a very small font size. A few participants highlighted that the use of pink font color for a risk

report might be too intimidating. In addition, some participants felt that the first page of the

report containing patient details, interpretation of risk, and disclaimer section was too lengthy,

they would prefer to have their results summarized on the first page of the report.

"In my opinion, the report [visual] is already good, [it is] also user-friendly in

[providing] medical information … Yet, the colors [of the background and text] are not

contrasting." (Indonesia FGD Participant 6, High-risk result report recipient)

"And also … like .. people normally focus on [text presented] in a larger font size,

maybe that is from me … so that [the information] can be more visible." (Indonesia FGD

Participant 12, Low-risk result report recipient)

"Report is comprehensive enough that it can give reassurance, but I am just

wondering will there be another color that you all can choose other than pink? … where

I am coming from is in terms of colors, it also brings across a message. If I give you a

report that is red, of course you will be scared right?" (Singapore FGD Participant 11,

High-risk result report recipient)

Subtheme 2.2 The content of the report

A. Summary Risk Group

Most of the participants felt that the summary risk group was clear. They could also

understand which combined risk group they belong to as well as knowing which group they

belong to according to the genetic and non-genetic risk. However, it was noted that some

participants felt that the "Interpretation of risk" table was difficult to understand despite having

explanation provided.

"… [the information around risk group is] already clear, [the report shows] that

the genetic risk [group] is low, the clinical risk [group] is also low … so there is overall

elevated risk" (Indonesia FGD Participant 7, High-risk result report recipient)

"I think the risk score is quite clear because they actually put a highlight for that..

I can tell whether I am in the high [risk] zone or the low [risk] zone …" (Singapore FGD

Participant 16, High-risk result report recipient)

B. Non-Genetic Risk

The explanation of non-genetic risk calculation was reported to be not very clear by those receiving low-risk reports. Most of them expressed that the explanation lacks clarity with the term "SEER" and how the percentage was being calculated. Most of them also reconfirmed if 1.3% was really the cutoff used to classify people into low- and high-risk groups. Some of them also asked which population data the score is generated from. Meanwhile, most participants receiving high-risk reports thought that the explanation was already clear.

"So ... there were only two [risk groups] for the non-genetic risk, right? Any score above 1.3 [%] would be classified into elevated [risk], right?" (Indonesia FGD Participant 3, Low-risk result report recipient)

"The bottom part about this SEER Registry... I think as a lay person, I wouldn't know what this is." (Singapore FGD Participant 7, Low-risk result report recipient)

C. Genetic Risk

Most participants felt that the explanation of genetic risk calculation was clear, except for the high-risk group participants from Indonesia. Overall, the participants felt that the graph was useful, and it helped them visualize which risk group they belonged to.

"The genetic risk score is quite clear because it has indicated the percentage clearly as well as there is a graph ... from the graph, I can differentiate what are the risk groups... and 5 years down the road, what will be the risk..." (Singapore FGD Participant 4, High-risk result report recipient)

However, participants who felt that the genetic risk calculation was unclear found the

supporting graph confusing, and they did not understand the term 'percentile'.

"... since not all people understand statistics, the use of word 'percentile' would

be confusing ...next, for the graph [of genetic risk] ... I understand [what the graph is

about] but it took a while for me to discern ... " (Indonesia FGD Participant 10, Low-risk

result report recipient)

"... next, for the graph [of genetic risk] ... I do not really understand ..."

(Indonesia FGD Participant 14, High-risk result report recipient)

D. Recommendations

The majority of participants found the recommended actions listed in the report to be

sufficient and useful. However, some participants felt that the recommendations lacked detail

and were too generic. For example, the lifestyle recommendations did not come with specific

fruits or vegetables the participants are suggested to take. It also did not inform what types of

physical activities are good to perform to reduce the risk of BC. There were also several

participants who suggested that the "link to evidence" should include credible websites that are

more layman-friendly instead of scientific publications.

"For myself, the lifestyle [recommendations] section is mostly clear, but it is too

general so patients may be questioning what foods should be eaten less or more ..."

(Indonesia FGD Participant 15, High-risk result report recipient)

"I feel that this is too generic, it's not personalized for me ... I feel that this is

something I can just get from the internet." (Singapore FGD Participant 3, Low-risk

result report recipient)

"Instead of having link to evidence, you could direct it to where I can find more

information and where I can read more about it ... because if I have a risk [of a certain

condition] or I have this condition, I will immediately go and google ... and you will read

all the scary things [on the internet] which might not even be credible or applicable to

you." (Singapore FGD Participant 9, Low-risk result report recipient)

Subtheme 2.3 Overall communication of the report

Feedback was given by study participants to improve the reader's understanding of the

report. Some participants suggested the addition of a glossary of medical terminologies may be

useful for people who do not have background in medicine or science. Additionally,

proofreading should have been done to give assurance to the clarity of information given in the

report.

"... [the report] may need a glossary [summarizing medical terminologies], I

think, as mentioned by Indonesia FGD Participant 1." (Indonesia FGD Participant 2,

Low-risk result report recipient)

Theme 3: Potential impacts of the BC risk assessment report

There were polarized reactions on how the participants would feel if the report prototype shown to them was really theirs. Negative emotions were shown by those receiving high-risk reports. All participants receiving high-risk reports said they would feel afraid, shocked, surprised, sad, worried, and anxious. However, there was one participant who would not feel shocked because she was aware that she has a family history of BC. On the contrary, most of the participants who received low-risk reports mentioned that they were relieved. Some of them also reported that they would not be negligent in maintaining a healthy lifestyle because the risk score may change over time.

"[If this report was really mine], I would feel afraid, for sure. Because I have past experience of losing my grandmother (to breast cancer). But, regardless, I will focus on the treatment [to reduce the risk] and the steps I could take to address this." (Indonesia FGD Participant 7, High-risk result report recipient)

"If I were the one who receives the report, I would automatically feel relieved. Even though the risk in the future will still exist and may change [to become higher] ..." (Indonesia FGD Participant 4, Low-risk result report recipient)

"I think I will be very worried if I receive a report that says my risk is high ... because one of my aunties has breast cancer ..." (Singapore FGD Participant 5, High-risk result report recipient)

Overall, most participants receiving high-risk results reported that there would be a positive change in the relationship with their physicians as they would consult and follow-up with their physicians more often. There were also participants who highlighted that the change in

relationship with their physicians would depend on the understanding of the physician towards

the report and the suggested interventions.

Meanwhile, all study participants receiving low-risk results in Indonesia thought they

would consult more frequently with qualified physicians to make sure their risk remained low.

Whereas in Singapore, all study participants receiving low-risk results reported that there would

be no changes in the relationship with their physicians.

" ... [I will be] consulting [with physician] more often; consulting [with

physician] what kind of lifestyle is recommended, what would happen if I skipped

[healthy eating and exercise] and cheated [from the recommendations] ... whether those

[nonadherent] things could increase the risk or not. I will ask more questions [to the

physician]." (Indonesia FGD Participant 15, High-risk result report recipient)

"Since we are in the low-risk group, there is no need to go and see my doctor

asking about the report ..." (Singapore FGD Participant 9, Low-risk result report

recipient)

The questions the participants would ask their physicians also varied. Regarding BC

monitoring and screening, participants from Indonesia would ask about the benefits and potential

side effects of mammography, while participants from Singapore would compare it against the

recommendations provided by the Ministry of Health (MOH) in Singapore. For lifestyle

modifications, participants would ask what kind of food to consume more or less as well as the

recommended types of physical activities. Participants would also ask about the recommended

drugs and the importance of surgical interventions. There were a few participants who were

interested in knowing how breast self-examination should be done.

"... what I would ask to my physician is on the type of mammography

[examination], whether it has [negative] effect to me [or not]?" (Indonesia FGD

Participant 4, Low-risk result report recipient)

"I don't know if your report is tailored to 40 - 49 years old ... Compared to MOH

recommendations, people over 50 [years old] don't have to go [for mammography] every

year ... but this is not on your report ... " (Singapore FGD Participant 7, Low-risk result

report recipient)

"Next, for the surgical [recommendation], [I may discuss] this later with a

genetic counselor, whether we who are at the [high] risk should undergo surgery or not,

maybe something like that, [so the question would be more on taking] a surgery [as an]

option." (Indonesia FGD Participant 7, High-risk result report recipient)

"For therapy, [I want to know] more details about the risks... What should be

done to reduce the risk? ... and more details about the therapy..." (Singapore FGD

Participant 4, High-risk result report recipient)"

"Next, second, maybe about the self-breast exam, I may ask more or confirm

[with my physician] about the exam, and how frequent I should do that." (Indonesia FGD

Participant 12, Low-risk result report recipient)

Other than their physician, the participants would want to share and discuss the result of

the genetic test with other parties. The majority of participants would like to share and discuss

the report with their family members or friends, particularly those having medical backgrounds

or having ever been diagnosed with BC.

389   *"With whom I would talk to other than my physician if get this report? Perhaps,*

390   *to my close friends or whoever [I know] who has ever been diagnosed with the same*

391   *disease, if there are any. If not, I would only discuss this with my physician or the*

392   *medical professionals [who take care of me]."* (Indonesia FGD Participant 4, Low-risk

393   result report recipient)

394   *"I will probably want to look at this report myself [and] do some research on my*

395   *own ... then probably talk to a family member then a doctor ..."* (Singapore FGD

396   Participant 6, High-risk result report recipient)"

The report also had the potential to change the participants' outlook on their personal

health. All of the participants receiving high-risk results felt that the report would help increase

their awareness of BC. They were also likely to change their lifestyle by following the

recommendations given. Similarly, most of the participants receiving low-risk results stated that

the report would change the way they view their health, their awareness of BC would also

increase, and they would be more mindful of taking preventive actions.

403   *"Yes, perhaps, [I would] be more aware, for example, that I would need to do*

404   *self-breast exam more regularly. Generally, I would be more aware [of the breast cancer*

405   *risk] due to the breast cancer risk prediction report I receive."* (Indonesia FGD

406   Participant 12, Low-risk result report recipient)

407   *"Since I know I am in the high-risk group, I have to [know] what are the*

408   *preventive methods I can take and moving forward ... how do I minimize the risk to*

409   *myself as much as I can."* (Singapore FGD Participant 6, High-risk result report

410   recipient)

Theme 4: The healthy women's perception and expectation of BC risk assessment testing

The majority of the study participants found the report useful. They were also excited to see risk assessment testing reports for other diseases in the future. Cervical cancer, diabetes and cardiovascular conditions were suggested by the study participants.

"[I want to see a similar report for] types of diseases that are related to cancer. For example, cervical cancer, and maybe [risk assessment testing] related to fertility." (Indonesia FGD Participant 14, High-risk result report recipient)

"I am just thinking about the most common fields ... people usually get diabetes, cancers..." (Singapore FGD Participant 11, High-risk result report recipient)

Discussion

To our knowledge, this FGD is one of the first studies conducted in Indonesia to evaluate the perception of healthy female participants towards testing results from personalized risk assessments for BC. Through the FGD, three areas of improvement for the detailed mock risk report were identified, which included the design, content, and communication styles of the report. These three areas coincide with recommendations by Farmer et al. [23] to improve understanding of patients and physicians to genetic test reports.

Firstly, regarding the design of the report, there was feedback from FGD participants to

avoid pink font color to make the result less intimidating. Some sections of the report were also

reported to be overly crowded with text. Similar findings were reported by Farmer et al. [23],

where the patients recommended avoiding dense blocks of text and using different colors to

differentiate 'positive' or 'negative' results.

Next, on the report content, this FGD found out that participants also demanded more

information on recommended actions they could take to reduce their risk of getting BC other

than improving the clarity of genetic and non-genetic risk information in the report. These

correspond with a study by Huang et al. [29] that found out that one of the three things that

affects people's decision to undergo predictive genetic testing is the availability of treatment and

prevention for the disease. The presence of recommended actions patients should take and

resources that enable them to access further information and support for the disease are what

patients are looking forward to in genetic testing report [23].

Lastly, the report should be communicated in a style that is understandable to patients

from non-healthcare professions. Not all patients understand medical or statistical jargon.

Therefore, the addition of a glossary could be very helpful for patients. Proofreading should also

be considered to make sure there are no typing errors or ambiguous interpretations. Even though

the report is not meant to be self-interpreted by patients themselves without consulting with

clinicians, making sure that patients understand the results of their risk assessment test is still

imperative. Furthermore, having a user-friendly report could help to improve communications

between the patients and their clinicians, thus allowing the counselling session to be more

effective [22]. Patients who do not clearly understand their test results tend to show lower

engagement in their personalized care [30] and are unable to adhere to recommended actions

[31]. As a result, they are more likely to fail in reducing or maintaining their risk level.

The insights obtained from our study are useful to optimize the delivery of personalized

risk assessment for BC. Most participants prefer a report that gives comprehensive information,

rather than only informing them to which risk group they belong. This is evident by the fact that

the majority of FGD participants in Singapore preferred the detailed report. Patients' preference

over comprehensive genetic testing reports is supported by a study by Brewer et al. [32]. In

addition to risk group, participants of the study could better understand their risk of getting BC

recurrence when they were given a report that clearly showed the risk score, brief information to

interpret the report as well as the graph depicting their position in the risk continuum.

The FGD identified the potential impacts of disclosing BC risk reports to patients.

Patients would feel anxious upon receiving high-risk results and relieved upon receiving low-risk

results from the testing. These findings correspond to the Singapore study conducted by Liow et

al. [33], where the participants reported to be living in fear if they learned that their risk of

acquiring BC was high. Given the nature of the testing as a diagnostic prediction, a negative

psychological impact could occur following the risk assessment testing regardless of the test

result. However, the anxiety level could be modest if patients understood what their report said

[34] and the testing was performed by expert teams [35]. This emphasizes the importance of

providing proactive personalized, pre- and post-test counselling conducted by counsellor who

has sufficient understanding in personalized risk assessment for BC. Although many testing

providers are now offering the option of delivering predictive genetic testing results via

telephone or letter for convenience, participants may value the opportunity of having an

individualized counselling session with the counsellor [36].

Our study found a key difference between Indonesian and Singaporean participants in our

FGD. With greater knowledge and awareness towards BC prevention among the Singaporeans, it

was observed that Singaporean participants receiving low-risk results would not want to have

additional follow-ups with their physicians as compared to the Indonesian participants.

Singaporean women may have a higher awareness level of BC screening due to the presence of

clinical BC screening subsidies that allow women over 50 years to undergo mammography every

two years at a more affordable cost [37]. However, the same initiative is absent in Indonesia, and

high cost has been reported to be one of the main barriers to access BC screening by Indonesian

[38]. This was also demonstrated by the disparity in understanding expressed toward

mammography, with participants in Indonesia being unfamiliar with the procedure. With the

inclusion of perspectives from two different countries of diverse ethnic groups that allowed for a

more comprehensive study, we are confident that the results of this study could be broadly

applicable to other Asian populations that share sociocultural similarities with Indonesia and

Singapore.

There is no universally accepted guideline to for test providers to ensure that their risk

assessment report is understandable by patients. Results from the Gail Model may not be easily

understood by patients [39,40]. Moreover, the format of reporting may impact the translation of

genetic test results into clinical recommendations, the interpretation of test results, and

ultimately, patients' adherence to the recommended actions [41,42]. Accordingly, it is

recommended that test providers that are planning to market their risk assessment services to

conduct studies aiming to gain feedback from potential customers and identify potential impacts

resulting from service that is still under development. Patients or healthcare service customers

could be involved in both the planning, development, and improvement of healthcare services

[43,44]. The World Health Organization highly recommends patient engagement [45] to ensure

that the delivered healthcare services result in maximum benefits and minimum risks for targeted

populations.

Studies aiming to seek feedback on the report from physicians are also warranted.

Participants, particularly those receiving high-risk results, would also consult more frequently

with their physician in the hope of reducing their risk level. They might consider seeing another

physician if the physician they are seeing now is unable to give appropriate recommendations to

act on their risk assessment report. This is imperative to make sure that the physicians, be it

specialists or non-specialists, can communicate the report clearly and discuss a personalized care

plan with their patients more comfortably. In addition, the FGD informed that the majority of the

study participants found the risk assessment report to be useful and were interested in seeing

similar reports for other diseases, including cancer, diabetes, and cardiovascular conditions.

These findings shed light on the other diseases patients demanded which test providers could

focus on in the future.

There were several limitations to this study. Since the focus groups were being conducted

in different languages, the use of scientific and medical related terms posed some limitations and

challenges during language translation, data analysis, and interpretation. Furthermore,

participants responses might not reflect their true emotions due to the use of mock reports.

Participants may have reacted differently if real reports had been used, especially for those

assigned to high-risk groups.

Conclusion

This study summarized how a BC risk assessment report can be personalized for each individual to facilitate the delivery of care plans for patients with different genetic and non-genetic risk profiles. With the increase in accessibility and availability of BC risk assessment service, many patients are interested in finding out more about their test results. Overall, most patients would prefer a test report to be well-balanced between content and complexity. The study also highlighted the importance of psychological impact of patients receiving their test report, which is greatly influenced by the patients' degree of understanding and interpretation of the reports. Finally, as most patients would likely increase their engagement with their physicians upon receiving their test results, future studies could be extended to physicians who are directly involved in the patient care delivery of BC prevention.

Acknowledgements

We would like to thank Professor Irwanto of Universitas Katolik Indonesia Atma Jaya for his guidance and training in the conduct and data analysis of focus group discussions.

References

1. World Health Organization. Breast cancer [Internet]. www.who.int. World Health Organization; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer

2. Yanes T, Young M-A, Meiser B, James PA. Clinical applications of Polygenic Breast Cancer Risk: A Critical Review and perspectives of an emerging field. Breast Cancer Research. 2020;22(1). doi:10.1186/s13058-020-01260-3

3. Hughes E, Wagner S, Pruss D, Bernhisel R, Probst B, Abkevich V, et al. Development and validation of a breast cancer polygenic risk score on the basis of genetic ancestry composition. JCO Precision Oncology. 2022 Nov 3;6. doi:10.1200/po.22.0008

4. Ohbe H, Hachiya T, Yamaji T, Nakano S, Miyamoto Y, Sutoh Y, et al. Development and validation of genome-wide polygenic risk scores for predicting breast cancer incidence in Japanese females: A population-based case-cohort study. Breast Cancer Research and Treatment. 2022;197(3):661–71. doi:10.1007/s10549-022-06843-6

5. Zeinomar N, Chung WK. Cases in precision medicine: The role of polygenic risk scores in Breast Cancer Risk Assessment. Annals of Internal Medicine. 2021 Mar 16;174(3):408–12. doi:10.7326/m20-5874

6. Duffy SW, Tabár L, Yen AM, Dean PB, Smith RA, Jonsson H, et al. Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women. Cancer. 2020 May 11;126(13):2971–9. doi:10.1002/cncr.32859

7. Lim ZL, Ho PJ, Khng AJ, Yeoh YS, Ong AT, Tan BK, et al. Mammography screening is associated with more favourable breast cancer tumour characteristics and better overall

survival: Case-only analysis of 3739 Asian Breast Cancer Patients. BMC Medicine. 2022 Aug 4;20(1). doi:10.1186/s12916-022-02440-y

8. Kowalski AE. Mammograms and Mortality: How Has the Evidence Evolved? The Journal of Economic Perspectives. 2021;35(2):119–40.

9. Løberg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. Breast Cancer Research. 2015 May 1;17(1). doi:10.1186/s13058-015-0525-z

10. Lim YX, Lim ZL, Ho PJ, Li J. Breast cancer in Asia: Incidence, mortality, early detection, mammography programs, and risk-based screening initiatives. Cancers. 2022 Aug 30;14(17):4218. doi:10.3390/cancers14174218

11. Fayanju OM, Kraenzle S, Drake BF, Oka M, Goodman MS. Perceived barriers to mammography among underserved women in A Breast Health Center Outreach Program. The American Journal of Surgery. 2014 Sept;208(3):425–34. doi:10.1016/j.amjsurg.2014.03.005

12. Rajendram P, Singh P, Han KT, Utravathy V, Wee HL, Jha A, et al. Barriers to breast cancer screening in Singapore: A literature review. Annals of the Academy of Medicine, Singapore. 2022 Aug 29;51(8):493–501. doi:10.47102/annals-acadmedsg.2021329

13. Ho PJ, Wong FY, Chay WY, Lim EH, Lim ZL, Chia KS, et al. Breast cancer risk stratification for mammographic screening: A nation☐wide screening cohort of 24,431 women in Singapore. Cancer Medicine. 2021 Oct 28;10(22):8182–91. doi:10.1002/cam4.4297

14. Pettersson A, Graff RE, Ursin G, dos Santos Silva I, McCormack V, Baglietto L, et al. Mammographic density phenotypes and risk of breast cancer: A meta-analysis. JNCI: Journal of the National Cancer Institute. 2014 May 10;106(5). doi:10.1093/jnci/dju078

15. Ho PJ, Tan IB, Chong DQ, Khor CC, Yuan J-M, Koh W-P, et al. Polygenic risk scores

for the prediction of common cancers in East Asians: A population-based prospective

cohort study. eLife. 2022 Sept 15;12. doi:10.7554/elife.82608

16. Ho PJ, Ho WK, Khng AJ, Yeoh YS, Tan BK-T, Tan EY, et al. Overlap of high-risk

individuals predicted by family history, and genetic and non-genetic breast cancer risk

prediction models: Implications for risk stratification. BMC Medicine. 2022 Apr

26;20(1). doi:10.1186/s12916-022-02334-z

17. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic risk

scores for prediction of breast cancer and breast cancer subtypes. The American Journal

of Human Genetics. 2018 Dec 13;104(1):21–34. doi:10.1016/j.ajhg.2018.11.002

18. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting

individualized probabilities of developing breast cancer for white females who are being

examined annually. JNCI Journal of the National Cancer Institute. 1989 Dec

20;81(24):1879–86. doi:10.1093/jnci/81.24.1879

19. Ho W-K, Tan M-M, Mavaddat N, Tai M-C, Mariapun S, Li J, et al. European polygenic

risk score for prediction of breast cancer shows similar performance in Asian women.

Nature Communications. 2020 Jul 31;11(1). doi:10.1038/s41467-020-17680-w

20. Ho W-K, Tai M-C, Dennis J, Shu X, Li J, Ho PJ, et al. Polygenic risk scores for

prediction of breast cancer risk in Asian populations. Genetics in Medicine. 2022 Jul

31;24(3):586–600. doi:10.1016/j.gim.2021.11.008

21. Chay WY, Ong WS, Tan PH, Jie Leo NQ, Ho GH, Wong CS, et al. Validation of the

GAIL model for predicting individual breast cancer risk in a prospective nationwide

study of 28,104 Singapore women. Breast Cancer Research. 2012 Jan 30;14(1). doi:10.1186/bcr3104

22. Haga SB, Mills R, Pollak KI, Rehder C, Buchanan AH, Lipkus IM, et al. Developing patient-friendly genetic and genomic test reports: Formats to promote patient engagement and understanding. Genome Medicine. 2014 Jul 31;6(7):58. doi:10.1186/s13073-014-0058-6

23. Farmer GD, Gray H, Chandratillake G, Raymond FL, Freeman AL. Recommendations for designing genetic test reports to be understood by patients and non-specialists. European Journal of Human Genetics. 2020 Feb 5;28(7):885–95. doi:10.1038/s41431-020-0579-y

24. Yuniar P, Kardinah K, Sinulingga D, Kartikawati A, Sirait, Lady, Widyastuti W, et al. Contextualizing policy implementation, challenges, and plans for improving breast cancer early detection programs in Indonesia. Research Square. 2022 Aug 4; doi:10.21203/rs.3.rs-1863931/v1

25. Loy EY, Molinar D, Chow KY, Fock C. National Breast Cancer Screening Programme, Singapore: Evaluation of participation and performance indicators. Journal of Medical Screening. 2015 Jun 16;22(4):194–200. doi:10.1177/0969141315589644

26. Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Social Science & Medicine. 2022 Jan 5;292:114523. doi:10.1016/j.socscimed.2021.114523

27. Hennink MM, Kaiser BN, Weber MB. What influences saturation? estimating sample sizes in Focus Group Research. Qualitative Health Research. 2019 Jan 10;29(10):1483–96. doi:10.1177/1049732318821692

28. Liu J, Ho PJ, Tan TH, Yeoh YS, Chew YJ, Mohamed Riza NK, et al. BREAst screening

Tailored for HEr (BREATHE)—A study protocol on personalised risk-based breast

cancer screening programme. PLOS ONE. 2022 Mar 31;17(3):1–14.

doi:10.1371/journal.pone.0265965

29. Huang M-Y, Huston SA, Perri M. Consumer preferences for the predictive genetic test

for Alzheimer disease. Journal of Genetic Counseling. 2013 Jul 12;23(2):172–8.

doi:10.100f7/s10897-013-9627-x

30. Elder NC, Barney K. "But what does it mean for me?" primary care patients'

communication preferences for test results notification. The Joint Commission Journal on

Quality and Patient Safety. 2012 Apr;38(4):168-AP1. doi:10.1016/s1553-7250(12)38022-

7

31. Chen W-T, Wantland D, Reid P, Corless IB, Eller LS, Iipinge S, et al. Engagement with

health care providers affects self- efficacy, self-esteem, medication adherence and quality

of life in people living with HIV. J AIDS Clin Res. 2013 Nov 1;04(01):256.

doi:10.4172/2155-6113.1000256

32. Brewer NT, Richman AR, DeFrank JT, Reyna VF, Carey LA. Improving communication

of breast cancer recurrence risk. Breast Cancer Research and Treatment. 2011 Oct

1;133(2):553–61. doi:10.1007/s10549-011-1791-9

33. Liow JJ, Lim ZL, Sim TM, Ho PJ, Goh S-A, Choy SD, et al. "It will lead you to make

better decisions about your health"—a focus group and survey study on women's

attitudes towards risk-based breast cancer screening and personalised risk assessments.

Current Oncology. 2022 Nov 25;29(12):9181–98. doi:10.3390/curroncol29120719

34. Woods SS, Schwartz E, Tuepker A, Press NA, Nazi KM, Turvey CL, et al. Patient
experiences with full electronic access to health records and clinical notes through the
My HealtheVet Personal Health Record Pilot: Qualitative Study. Journal of Medical
Internet Research. 2013 Mar 27;15(3):e65. doi:10.2196/jmir.2356

35. Bordet C, Brice S, Maupain C, Gandjbakhch E, Isidor B, Palmyre A, et al. Psychosocial
impact of predictive genetic testing in hereditary heart diseases: The PREDICT study.
Journal of Clinical Medicine. 2020 May 6;9(5):1365. doi:10.3390/jcm9051365

36. O'Shea R, Meany M, Carroll C, Cody N, Healy D, Green A, et al. Predictive genetic
testing and alternatives to face to face results disclosure: A retrospective review of
patients preference for alternative modes of BRCA 1 and 2 results disclosure in the
Republic of Ireland. Journal of Genetic Counseling. 2015 Sept 26;25(3):422–31.
doi:10.1007/s10897-015-9887-8

37. Breast screening subsidies in Singapore [Internet]. [cited 2023 May 30]. Available from:
https://www.healthhub.sg/a-z/costs-and-financing/30/breast-cancer-screening-subsidies

38. Choridah L, Icanervilia AV, de Wit MJ, van Asselt ADI, Kurniawan WT, Fahmi YI, et
al. Knowledge and acceptance towards mammography as breast cancer screening tool
among Yogyakarta Women and Health Care Providers (mammography screening in
Indonesia). Journal of Cancer Education. 2019 Nov 27;36(3):532–7. doi:10.1007/s13187-
019-01659-3

39. Stevanato K, Pedroso R, Dell Agnolo C, Santos L, Pelloso F, Carvalho M, et al. Use and
applicability of the Gail model to calculate breast cancer risk: A scoping review. Asian
Pacific   Journal   of   Cancer   Prevention.   2022;23(4):1117–23.
doi:10.31557/apjcp.2022.23.4.1117

40. Komen SG. Estimating breast cancer risk (GAIL model) [Internet]. 2023 [cited 2023 May 29]. Available from: https://www.komen.org/breast-cancer/risk-factor/understanding-risks/gail-method/

41. Hao L, Kraft P, Berriz GF, Hynes ED, Koch C, Korategere V Kumar P, et al. Development of a clinical polygenic risk score assay and reporting workflow. Nature Medicine. 2022 Apr 18;28(5):1006–13. doi:10.1038/s41591-022-01767-6

42. Lewis ACF, Green RC, Vassy JL. Polygenic risk scores in the clinic: Translating risk into action. Human Genetics and Genomics Advances. 2021 Oct 14;2(4):100047. doi:10.1016/j.xhgg.2021.100047

43. Crawford MJ, Rutter D, Manley C, Weaver T, Bhui K, Fulop N, et al. Systematic review of involving patients in the planning and development of health care. BMJ. 2002 Nov 30;325(7375):1263. doi:10.1136/bmj.325.7375.1263

44. Bergerum C, Engström AK, Thor J, Wolmesjö M. Patient involvement in quality improvement – a 'tug of war' or a dialogue in a learning process to improve healthcare? BMC Health Services Research. 2020 Dec 2;20(1). doi:10.1186/s12913-020-05970-4

45. World Health Organization. Patient engagement [Internet]. Geneva: World Health Organization; 2016 [cited 2023 May 29]. 26 p. (Technical Series on Safer Primary Care). Available from: https://apps.who.int/iris/handle/10665/252269

Supporting information

691   **S1 File. SRQR Checklist**

692   **S2 File. Detailed Report Prototype**

693   **S3 File. FGD Question List**

694   **S4 File. Simplified Report Prototype**